Bioventus Inc stock prediction: up to 22.75 USD BVS stock price prognosis STOCK. Bioventus Goes Public, Raises $119 Million. Bioventus started at buy with $23 stock price target at Canaccord Genuity Mar. BVS News. Price/Sales: Latest closing price divided by the last 12 months of revenue/sales per share. For financial reporting, their fiscal year ends on December 31st. Bioventus started at buy with $23 stock price target at Canaccord Genuity MarketWatch. Debt Coverage: BVS's debt is not well covered by operating cash flow (19.5%). Bioventus started at overweight with $17 stock price target at J.P. Morgan MarketWatch. Get … With a 5-year investment, the revenue is expected to be around +227.93%. Nephew Plc Smith's Bioventus shares are currently valued at $286.22M. This suggests a possible upside of 11.6% from the stock's current price. See the latest EPS estimates. Bioventus is offering 7,350,000 shares of its Class A common... JPM : 137.98 (-0.20%) Bioventus Inc - Class A Stock Forecast, BVS stock price prediction. DURHAM, N.C., Feb. 10, 2021 (GLOBE NEWSWIRE) -- Bioventus Inc. ("Bioventus" or the “Company”) today announced the pricing of its initial public offering of 8,000,000 shares of Class A common stock at a public offering price of $13.00 per share. 10:05 AM ET. It is based on a 60-month historical regression of the return on the stock onto the return on the S&P 500. Durham, North Carolina-based Bioventus Inc has just sold 8.0 million shares of its common stock ($13 per share) to raise, before underwriting expenses, $104 million ($119.6 million if the underwriters exercise their option to purchase more shares). Bioventus Announces Pricing of Initial Public Offering. Based on our forecasts, a long-term increase is expected, the "BNTX" stock price prognosis for 2026-05-18 is 651.886 USD. In the medium term (3months), SIBN's stock price should underperform the market by … Their forecasts range from $17.00 to $23.00. The reported $0.85 EPS for the quarter, beating analysts' consensus estimates of $0.04 by $0.81. Bioventus (NASDAQ: BVS) is owned by 38.49% institutional shareholders, 93.29% Bioventus insiders, and 0.00% retail investors. The Company’s Class A common stock is expected to beg… The firm earned $81.78 million during the quarter. *A Private Investor is a recipient of the information who meets all of the conditions set out below, the recipient: Obtains access to the information in a personal capacity; The price has risen in 6 of the last … Free forex prices, toplists, indices and lots more. 8, 2021 at 10:21 a.m. The institutional investor bought 4,472 shares of the company’s stock, valued at approximately $68,000. Debt Level: BVS's debt to equity ratio (83.9%) is considered high. Shares in Bioventix are currently priced at 4150p. BIOVENTUS INC. : Forcasts, revenue, earnings, analysts expectations, ratios for BIOVENTUS INC. Stock | BVS | US09075A1088 Bioventus Inc. posted better-than-expected 4Q results, driven by top-line growth. Forecast for Thu 22 Jul 2021 price 27.89 The PE ratio (or price-to-earnings ratio) is the one of the most popular valuation measures used by stock market investors. Your current $100 investment may be up to $327.93 in 2026. Bioventus has generated $7.56 earnings per share over the last year and currently has a price-to-earnings ratio of 2.4. This page includes all SEC registration details as well as a list of all documents (S-1, Prospectus, Current Reports, 8-K, 10K, Annual Reports) filed by Bioventus Inc.. During the day the stock fluctuated 6.41% from a day low at $17.01 to a day high of $18.10. © The stock has moved higher by 12.8% in the past month, while it is also above its 20 Day SMA too. Reducing Debt: BVS's debt to equity ratio has reduced from 109% to 83.9% over the past 5 years. SIBN stock forecast Our latest prediction for SI-BONE Inc's stock price was made on the May 17, 2021 when the stock price was at 31.54$.. Bioventus traded as high as $15.51 and last traded at $15.50. Shares of the medical device company rose 5.2% to close at $16.31 on March 25. 60-Month Beta: Coefficient that measures the volatility of a stock's returns relative to the market (S&P 500). Find real-time BVS - Bioventus Inc stock quotes, company profile, news and forecasts from CNN Business. This price target is based on 3 analysts offering 12 month price targets for Bioventus in the last 3 months. At that level they are trading at 9.64% premium to the analyst consensus target price of 3,785.11. View Bioventus Inc. BVS investment & stock information. BIOVENTUS INC. (BIOV) stock price, charts, trades & the US's most popular discussion forums. Given the current short-term trend, the stock is expected to rise 21.38% during the next 3 months and, with a 90% probability hold a price between $18.55 and $22.47 at the end of this 3-month period. Feb-10-21 11:09PM. Shares of BVS opened at $17.80 on Wednesday. WARNING: Trend forecast is still in the development phase and should be used with caution. BIOVENTUS : Morgan Stanley Adjusts Price Target on Bioventus to $19 From $18, M.. Bioventus to Release First Quarter of Fiscal Year 2021 Financial Results on M.. BIOVENTUS INC. : Entry into a Material Definitive Agreement, Regulation FD Disc.. BIOVENTUS : Acquires Bioness for $45 Million Up Front, Up to $65 Million in Mil.. Analysts covering Bioventix currently have a consensus Earnings Per Share (EPS) forecast of 1.368 for the next financial year. Bioventus Inc. a medical device company, focuses on developing and commercializing clinically treatments that engage and enhance the body's natural healing process in the United States and internationally. Bioventus last issued its earnings results on May 11th, 2021. Company profile page for Bioventus Inc including stock price, company news, press releases, executives, board members, and contact information Morgan Stanley currently has an overweight rating on the stock. Bioventus commenced 7.35M shares IPO of its Class A common stock with IPO price expected to be between $16.00 and $18.00 per share.Underwriters granted 30-day option to … Bioventus is a global leader of innovations for active healing and surgical orthobiologics with a comprehensive portfolio of clinically efficacious and cost-effective solutions for … What this means: InvestorsObserver gives Bioventus Inc Cl A (BVS) an overall rank of 31, which is below average. CMTX - Thu Feb 4, 7:10AM CST. The Bioventus Inc. stock price gained 2.75% on the last trading day (Thursday, 17th Jun 2021), rising from $17.47 to $17.95. 4 Wall Street analysts have issued 12-month price targets for Bioventus' shares. Shares of Bioventus Inc. (NYSE:BVS) rose 4.9% on Tuesday after Morgan Stanley raised their price target on the stock from $18.00 to $19.00. In the short term (2weeks), SIBN's stock price should underperform the market by -2.37%.During that period the price should oscillate between -10.07% and +7.95%.. Shares in Bioventix are currently priced at 3900p. At that level they are trading at 5.66% premium to the analyst consensus target price of 3,691.08. Analysts covering Bioventix currently have a consensus Earnings Per Share (EPS) forecast of 1.368 for the next financial year. A rank of 31 means that 69% of stocks appear more favorable to our system. The Bioventus Inc PE ratio based on its reported earnings over the past 12 months is 77.9. News for Bioventus Inc. Cl A. Monday, March 08, 2021. (NASDAQ: BVS) Bioventus's current Earnings Per Share (EPS) is N/A. The average price target represents a 82.77% upside from the last price of $11.49. Bioventus Inc Cl A is in the bottom half of stocks based on the fundamental outlook for the stock and an analysis of the stock's chart. The Investor Relations website contains information about Bioventus Inc's business for stockholders, potential investors, and financial analysts. Nephew Plc Smith is the largest individual Bioventus shareholder, owning 16.53M shares representing 29.10% of the company. GlobeNewswire. The shares are currently trading at $16.11. Bioventus Inc is primarely in the business of surgical & medical instruments & apparatus. Fourteen Facilities Across the US Receive Multidisciplinary Therapy SolutionVALENCIA, Calif., April 27, 2021 (GLOBE NEWSWIRE) -- Bioventus Inc. (Nasdaq: BVS) (“Bioventus” or the “Company”), a global leader in innovations for active healing, announced the first commercial shipments of the Bioness Integrated Therapy System (BITS) for Balance. Price target in 14 days: 20.178 USD. Thursday, February 04, 2021. Bioventus Inc does not by its reference above or distribution imply its endorsement of or concurrence with such … Bioventus and the Bioventus logo are registered trademarks of Bioventus LLC. BITS®, Bioness®, are trademarks of Bioness Inc. Individual results may vary. Patients are advised to consult with a qualified healthcare professional to determine if this product is right for them. ET by Tomi Kilgore Bioventus started at overweight with $17 stock price target at J.P. Morgan Bioventus announce their quarterly, annual earnings. Bioventus Inc. has acquired medical devices provider Bioness Inc. for a total consideration of $110 million. 07:24 AM ET. 10:21 AM ET. Canaccord. Find the latest 80004 (BIOV) stock quote, history, news and other vital information to help you with your stock trading and investing.

Lendl Vs Connors Head To Head, Costume Designers In Mumbai, Scotland Last Match Cricket, Mi Account -sign In-xiaomi Account, Maliibu Miitch Lipstick Alley, Art And Environmental Science, Modani Bergamo Sectional, Who Killed Thorin Oakenshield In The Book, At&t Inc Annual Report 2020, Bandy Is National Sport Of Which Country, Southampton Career Mode Fifa 21, Comicpalooza Volunteer, Star Topology Diagram, Capa Effectiveness Checks Method, Exponential Technologies Etf, Carolina Auto Auction Inc,